Passage Bio
PASG
71 hedge funds and large institutions have $817M invested in Passage Bio in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 13 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 11
103% more capital invested
Capital invested by funds: $403M → $817M (+$415M)
1% more funds holding
Funds holding: 70 → 71 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0.13% more ownership
Funds ownership: 3.38% → 3.51% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
BlackRock
New York
|
+$14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.39M |
| 4 |
JP Morgan Chase
New York
|
+$3.75M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.28M |
Top Sellers
PASG Hedge Fund Activity: Q4 2020 in Review
71 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2020, worth a combined $817M — up 103% from $403M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PASG positions and 13 closed out — a net gain of 1 holder — while 33 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $14M. The largest seller was Vivo Capital, cutting an estimated $14.1M.
- 71 institutional investors held Passage Bio (PASG) as of Q4 2020, up from 70 in Q3 2020.
- Funds reported $817M of Passage Bio stock for Q4 2020, up 103% quarter-over-quarter.
- 14 funds opened new Passage Bio positions in Q4 2020 and 13 closed out, a net change of +1 holder.
- The largest Passage Bio buyer in Q4 2020 was BlackRock, an estimated $14M added.
- The largest Passage Bio seller in Q4 2020 was Vivo Capital, an estimated $14.1M sold.
Based on aggregated 13F filings for Q4 2020.